0 187

Cited 0 times in

Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma

Authors
 Cheolhee Won  ;  Byung-Hak Kim  ;  Eun Hee Yi  ;  Kyung-Ju Choi  ;  Eun-Kyung Kim  ;  Jong-Min Jeong  ;  Jae-Ho Lee  ;  Ja-June Jang  ;  Jung-Hwan Yoon  ;  Won-Il Jeong  ;  In-Chul Park  ;  Tae Woo Kim  ;  Sun Sik Bae  ;  Valentina M. Factor  ;  Stephanie Ma  ;  Snorri S. Thorgeirsson  ;  Yun-Han Lee  ;  Sang-Kyu Ye 
Citation
 Hepatology, Vol.62(4) : 1160-1173, 2015 
Journal Title
 Hepatology 
ISSN
 0270-9139 
Issue Date
2015
Abstract
Enhanced expression of the cancer stem cell (CSC) marker, CD133, is closely associated with a higher rate of tumor formation and poor prognosis in hepatocellular carcinoma (HCC) patients. Despite its clinical significance, the molecular mechanism underlying the deregulation of CD133 during tumor progression remains to be clarified. Here, we report on a novel mechanism by which interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) signaling up-regulates expression of CD133 and promotes HCC progression. STAT3 activated by IL-6 rapidly bound to CD133 promoter and increased protein levels of CD133 in HCC cells. Reversely, in hypoxic conditions, RNA interference silencing of STAT3 resulted in decrease of CD133 levels, even in the presence of IL-6, with a concomitant decrease of hypoxia-inducible factor 1 alpha (HIF-1α) expression. Active STAT3 interacted with nuclear factor kappa B (NF-κB) p65 subunit to positively regulate the transcription of HIF-1α providing a mechanistic explanation on how those three oncogenes work together to increase the activity of CD133 in a hypoxic liver microenvironment. Activation of STAT3 and its consequent induction of HIF-1α and CD133 expression were not observed in Toll-like receptor 4/IL-6 double-knockout mice. Long-term silencing of CD133 by a lentiviral-based approach inhibited cancer cell-cycle progression and suppressed in vivo tumorigenicity by down-regulating expression of cytokinesis-related genes, such as TACC1, ACF7, and CKAP5. We also found that sorafenib and STAT3 inhibitor nifuroxazide inhibit HCC xenograft formation by blocking activation of STAT3 and expression of CD133 and HIF-1α proteins. CONCLUSION: IL-6/STAT3 signaling induces expression of CD133 through functional cooperation with NF-κB and HIF-1α during liver carcinogenesis. Targeting STAT3-mediated CD133 up-regulation may represent a novel, effective treatment by eradicating the liver tumor microenvironment.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141648
DOI
10.1002/hep.27968
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원)
Yonsei Authors
이윤한(Lee, Yun Han) ; 최경주(Choi, Kyung Ju)
사서에게 알리기
  feedback
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/hep.27968/abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse